Genomtec S.A.

Regulatory Filings • Feb 28, 2024

TheExecutive Board of Genomtec S.A. ("Company", "Issuer") registered inWroclaw, Poland, hereby reports that today The Company has learned abouta positive decision of the Patent Office of the Republic of Polandgranting the Company patent protection for an invention entitled "Zestawstarterów do powielania sekwencji nukleotydowej genu dnaE Mycoplasmapneumoniae, sposób wykrywania bakterii Mycoplasma pneumoniae, sposóbwykrywania infekcji bakterią Mycoplasma pneumoniae oraz zestaw dowykrywania infekcji bakterią Mycoplasma pneumoniae". Granting a patentis conditional on the Issuer paying the required official fees for whichthe Management Board of Genomtec S.A. has agreed.

Theinvention covers significant technical solutions related to the area ofmolecular biology of the Genomtec ID platform significantly affectingthe diagnostic parameters of the RP5-Plex panel detecting the mostcommon causes of respiratory infections.

TheIssuer informs that this is the twelfth patent received by the Company.The Issuer is pending over thirty patent applications all over the world.TheIssuer's Management Board decided that the receipt of the above patentis confidential information, as in the case of an entity operating onthe molecular diagnostics market, it is necessary to effectively protectintellectual and industrial property. Properly secured intellectual andindustrial property may constitute the Issuer's competitive advantage -and its safe commercialization is possible provided that full protectionis ensured on selected markets.Inthe opinion of the Management Board, a high level of intellectualproperty protection will also provide the Company with an appropriatenegotiating position before signing commercial agreements with selectedpartners in the scope of implementing the commercialization strategy.Patentproceedings are aimed at securing key interests and are in line with theIssuer's development strategy, which includes building a portfolio ofintellectual property rights. POCT diagnostics using the Genomtec IDplatform is the key area of the Issuer's operations. For these reasons,in the opinion of the Management Board, this information meets thecriteria of confidential information within the meaning of Art. 7 sec. 1MAR.